PL360780A1 - Środki farmaceutyczne zawierające inhibitory fosforylazy glikogenu - Google Patents

Środki farmaceutyczne zawierające inhibitory fosforylazy glikogenu

Info

Publication number
PL360780A1
PL360780A1 PL36078001A PL36078001A PL360780A1 PL 360780 A1 PL360780 A1 PL 360780A1 PL 36078001 A PL36078001 A PL 36078001A PL 36078001 A PL36078001 A PL 36078001A PL 360780 A1 PL360780 A1 PL 360780A1
Authority
PL
Poland
Prior art keywords
pharmaceutical compositions
glycogen phosphorylase
phosphorylase inhibitors
inhibitors
glycogen
Prior art date
Application number
PL36078001A
Other languages
English (en)
Inventor
Dennis Jay Hoover
Ravi Mysore Shanker
Dwayne Thomas Friesen
Douglas Alan Lorenz
James Alan Schriver Nightingale
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of PL360780A1 publication Critical patent/PL360780A1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
PL36078001A 2000-03-16 2001-03-16 Środki farmaceutyczne zawierające inhibitory fosforylazy glikogenu PL360780A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18994200P 2000-03-16 2000-03-16
PCT/IB2001/000394 WO2001068055A1 (en) 2000-03-16 2001-03-16 Pharmaceutical compositions of glycogen phosphorylase inhibitors

Publications (1)

Publication Number Publication Date
PL360780A1 true PL360780A1 (pl) 2004-09-20

Family

ID=22699402

Family Applications (1)

Application Number Title Priority Date Filing Date
PL36078001A PL360780A1 (pl) 2000-03-16 2001-03-16 Środki farmaceutyczne zawierające inhibitory fosforylazy glikogenu

Country Status (32)

Country Link
US (1) US20010053778A1 (pl)
EP (1) EP1263414A1 (pl)
JP (1) JP2003526654A (pl)
KR (1) KR20020081445A (pl)
CN (1) CN1418089A (pl)
AP (1) AP2002002621A0 (pl)
AR (1) AR027656A1 (pl)
AU (1) AU2001242669A1 (pl)
BG (1) BG107037A (pl)
BR (1) BR0109189A (pl)
CA (1) CA2403241A1 (pl)
CO (1) CO5280087A1 (pl)
CZ (1) CZ20022955A3 (pl)
EA (1) EA200200858A1 (pl)
EE (1) EE200200530A (pl)
HU (1) HUP0204583A2 (pl)
IL (1) IL151320A0 (pl)
IS (1) IS6508A (pl)
MA (1) MA26882A1 (pl)
MX (1) MXPA02009097A (pl)
NO (1) NO20024386L (pl)
OA (1) OA12232A (pl)
PA (1) PA8513601A1 (pl)
PE (1) PE20011184A1 (pl)
PL (1) PL360780A1 (pl)
SK (1) SK12622002A3 (pl)
SV (1) SV2002000343A (pl)
TN (1) TNSN01040A1 (pl)
TR (1) TR200202184T2 (pl)
WO (1) WO2001068055A1 (pl)
YU (1) YU67202A (pl)
ZA (1) ZA200207290B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006402B1 (ru) * 1999-12-23 2005-12-29 Пфайзер Продактс Инк. Комбинация лекарства и целлюлозного полимера, повышающего концентрацию; способ введения лекарства и водный раствор (варианты)
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
MXPA03011935A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
EP1404300B1 (en) 2001-06-22 2009-09-30 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
HUP0400281A3 (en) 2001-06-22 2009-11-30 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug and process for their preparation
EP1469830A2 (en) 2002-02-01 2004-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
RU2278659C9 (ru) 2002-02-01 2007-02-20 Пфайзер Продактс Инк. Способ получения гомогенных, высушенных распылением твердых аморфных дисперсий лекарственного средства с использованием модифицированной установки сушки распылением
JP2005523262A (ja) 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
EP1701704A2 (en) * 2003-12-31 2006-09-20 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
ES2353309T3 (es) 2004-03-08 2011-03-01 Prosidion Ltd. Hidrazidas del ácido pirrolopiridin-2-carboxílico como inhibidores de glucógeno fosforilasa.
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
CN104755504A (zh) * 2012-08-24 2015-07-01 陶氏环球技术有限责任公司 新的具有高分子量和均匀性的酯化纤维素醚
DK3725778T3 (da) 2012-09-11 2021-09-20 Medivation Prostate Therapeutics Llc Formuleringer af enzalutamid
EP3763702B1 (en) * 2013-07-19 2023-12-13 Siga Technologies, Inc. Preparation of amorphous tecovirimat dispersions
CN103709171B (zh) * 2014-01-20 2015-09-16 武汉大学 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
CA2342471C (en) * 1995-06-06 2002-10-29 Judith L. Treadway Heterocyclecarbonylmethyl amine intermediates
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
EP1263414A1 (en) 2002-12-11
IS6508A (is) 2002-08-16
NO20024386D0 (no) 2002-09-13
WO2001068055A1 (en) 2001-09-20
YU67202A (sh) 2006-01-16
HUP0204583A2 (hu) 2003-04-28
MA26882A1 (fr) 2004-12-20
CN1418089A (zh) 2003-05-14
AU2001242669A1 (en) 2001-09-24
IL151320A0 (en) 2003-04-10
CZ20022955A3 (cs) 2003-09-17
CA2403241A1 (en) 2001-09-20
BG107037A (bg) 2003-04-30
EA200200858A1 (ru) 2003-02-27
EE200200530A (et) 2004-04-15
CO5280087A1 (es) 2003-05-30
ZA200207290B (en) 2003-09-11
BR0109189A (pt) 2003-05-27
SK12622002A3 (sk) 2004-02-03
US20010053778A1 (en) 2001-12-20
JP2003526654A (ja) 2003-09-09
TR200202184T2 (tr) 2003-01-21
OA12232A (en) 2006-05-10
TNSN01040A1 (fr) 2005-11-10
AP2002002621A0 (en) 2002-09-30
KR20020081445A (ko) 2002-10-26
AR027656A1 (es) 2003-04-09
PA8513601A1 (es) 2004-08-31
NO20024386L (no) 2002-11-13
SV2002000343A (es) 2002-07-03
MXPA02009097A (es) 2003-03-12
PE20011184A1 (es) 2001-11-15

Similar Documents

Publication Publication Date Title
IL151320A0 (en) Pharmaceutical compositions of glycogen phosphorylase inhibitors
HU0101158D0 (en) Use of glycogen phosphorylase inhibitors
HUP0302412A3 (en) Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same
HUP0500173A3 (en) Alpha-sulphonamido-acetamide derivatives as beta-amyloid inhibitors and pharmaceutical compositions containing them
HUP0400451A3 (en) Pyrrole derivatives and pharmaceutical compositions containing them
HUP0303108A3 (en) Substituted pyrazoles and pharmaceutical compositions containing them
HUP0401950A3 (en) Pyrimidine derivatives and pharmaceutical compositions containing that compounds
HUP0400641A3 (en) Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
HUP0401819A3 (en) Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
HUP0401711A3 (en) N-heterocyclic inhibitors of tnf-alpha and pharmaceutical compositions containing them
AU9025701A (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containingthe same
HUP0103575A3 (en) Inhibitors of caspases, pharmaceutical compositions comprising thereof and their use
HUP0302485A3 (en) Arylmethylamine derivatives for use as tryptase inhibitors and pharmaceutical compositions containing them
HUP0201011A2 (en) Aminopyrimidines as sorbitol dehydrogenase inhibitors and pharmaceutical compositions containing them
HUP0302358A3 (en) Piperazinedione compounds and use of them for producing pharmaceutical compositions
HUP0401333A3 (en) Spiropyrazole compounds and pharmaceutical compositions containing them
HUP0303998A3 (en) Phthalazinones derivatives and pharmaceutical compositions containing them
IL158236A0 (en) Pharmaceutical compositions containing azithromycin and derivatives thereof
HUP0303184A3 (en) Substituted c-cyclohexylmethylamine derivatives and pharmaceutical compositions containing them
HUP0400654A3 (en) Substituted 8-arylquinoline phosphodiesterase 4 inhibitors and pharmaceutical compositions containing them
HUP0303279A3 (en) Indolylopyrrolocarbazoles sugar derivatives as topoisomerase inhibitors and pharmaceutical compositions containing them
HUP0303731A3 (en) Sulfonylguanidines and their use for preparation of pharmaceutical compositions
HUP0303204A3 (en) 1-methylcarbapenem derivatives and pharmaceutical compositions containing them
HUP0302397A3 (en) Heterocyclic compounds and pharmaceutical compositions containing them
HUP0303074A3 (en) Benzodiazepine derivatives and pharmaceutical compositions them

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)